Our impact

The National Foundation for Medical Research and Innovation has implemented a strategy focused on supporting gap areas along the innovation pathway for biomedical research.

This targeted support assists researchers to advance their research towards the development of new innovations including medicines, vaccines, diagnostics and devices.  These innovations normally require regulatory approval, commercial partnerships and investors as they progress.  Learn more.

2018

A new vaccine to prevent infections with Group A Streptococcus

A new vaccine to prevent infections with Group A Streptococcus
Prof Michael Good AO
Griffith University
Rheumatic Heart Disease and Streptococcus A infections
Vaccine

 

Key outcomes:

  • Development collaboration with major pharmaceutical company
  • Clinical trials commencing in 2018.

“NFMRI funding for our streptococcal vaccine project has provided critical leverage to enable us to secure funds for the clinical aspects of our Phase I trial, which would not have been possible without the ability to produce GMP-grade vaccine and to undertake formal toxicology studies on the vaccine. If the vaccine is successful, then much credit will be owing to NFMRI and their willingness to help us through this important phase in vaccine development”

Read more
2017

Novel agents for the treatment of cardiac fibrosis

Novel agents for the treatment of cardiac fibrosis
A/Prof Bernard Flynn
Monash University
Cardiac fibrosis
Therapeutic

Key outcomes:

  • Negotiating spin-off company opportunity

“NFMRI funding has enabled us to access the services of the Centre for Drug Candidate Optimization and to demonstrate that our antifibrotic drug molecules are suitable for oral administration. This data has been critical in attracting Venture Capital support for the formation of a spin-out company in 2018 that will enable us to bring our fibrosis therapy to clinical trials.”

Read more
2017

Detection and diagnostic device – lab on a chip for infectious diseases

Detection and diagnostic device – lab on a chip for infectious diseases
Prof Stephen Haswell
Deakin University
Infectious diseases
Diagnostic

Key outcomes:

  • Developed working prototype
  • Mobile device providing results in approximately 75 minutes
  • Costing around $20 per test
  • Exploring product development pathways.

“The funding will enable an impressive team drawn from chemistry, biology, engineering, manufacturing and end users to work with NFMRI and NSW DPI to develop novel lab-on-a-chip technology that will represent a paradigm shift in the provision of medical diagnostics and care, filling a great unmet need.”

Read more
2016

Towards an improved allergen immunotherapy vaccine targeting subtropical grass pollens

Towards an improved allergen immunotherapy vaccine targeting subtropical grass pollens
A/Prof Janet Davies
Queensland University of Technology
Grass Allergies and Asthma
Vaccine

 

Key outcomes:

  • A/Prof Davies was a finalist in the Queensland State Government and Johnson & Johnson Innovation Quick Fire Challenge
  • Dr Davies was promoted to Associate Professor and accepted a position at the Queensland University of Technology
  • Currently in discussion with a number of potential commercial partners.

“I am and will remain grateful for having received the financial support from the Foundation and for the opportunities the grant afforded me. Perhaps beyond the tangible, the greatest benefit may well be the learning and growth in knowledge and experience in the commercial side of translation that this project has provided.”

Read more

make-a-donation

partner-enquiry

thinking-out-land

Loading

Looking beyond the research and considering translational needs when funding research. How well are your expectations, application and review processes, measures of success and funding strategy aligned with the next steps for translation?

Thank you for voting
You have already voted on this poll!
Please select an option!

    Supporters